- Home
- LPTX vs IVA Comparison
LPTX vs IVA Comparison
Compare LPTX & IVA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LPTX
- IVA
- Stock Information
- Founded
- LPTX 2011
- IVA 2011
- Country
- LPTX United States
- IVA France
- Employees
- LPTX N/A
- IVA N/A
- Industry
- LPTX Biotechnology: Biological Products (No Diagnostic Substances)
- IVA Biotechnology: Pharmaceutical Preparations
- Sector
- LPTX Health Care
- IVA Health Care
- Exchange
- LPTX Nasdaq
- IVA Nasdaq
- Market Cap
- LPTX 117.1M
- IVA 117.3M
- IPO Year
- LPTX N/A
- IVA 2020
- Fundamental
- Price
- LPTX $2.74
- IVA $2.72
- Analyst Decision
- LPTX Strong Buy
- IVA Strong Buy
- Analyst Count
- LPTX 4
- IVA 4
- Target Price
- LPTX $8.63
- IVA $14.00
- AVG Volume (30 Days)
- LPTX 452.0K
- IVA 40.6K
- Earning Date
- LPTX 11-13-2024
- IVA 09-25-2024
- Dividend Yield
- LPTX N/A
- IVA N/A
- EPS Growth
- LPTX N/A
- IVA N/A
- EPS
- LPTX N/A
- IVA N/A
- Revenue
- LPTX N/A
- IVA $20,652,523.00
- Revenue This Year
- LPTX N/A
- IVA N/A
- Revenue Next Year
- LPTX N/A
- IVA $361.78
- P/E Ratio
- LPTX N/A
- IVA N/A
- Revenue Growth
- LPTX N/A
- IVA N/A
- 52 Week Low
- LPTX $1.55
- IVA $1.53
- 52 Week High
- LPTX $5.00
- IVA $4.75
- Technical
- Relative Strength Index (RSI)
- LPTX 39.77
- IVA 58.08
- Support Level
- LPTX $3.40
- IVA $2.52
- Resistance Level
- LPTX $3.61
- IVA $2.85
- Average True Range (ATR)
- LPTX 0.40
- IVA 0.13
- MACD
- LPTX -0.13
- IVA -0.02
- Stochastic Oscillator
- LPTX 1.91
- IVA 61.19
About LPTX Leap Therapeutics Inc.
Leap Therapeutics Inc is in developing targeted antibody therapies for cancer treatment, focusing on inhibiting tumor-promoting pathways, targeting cancer-specific cell surface molecules, and activating the immune system against cancer cells. The company's lead program, DKN-01, targets Dickkopf-related protein 1 (DKK1) and is in clinical trials for esophagogastric, gynecologic, and colorectal cancers. Their second program, FL-301, targets Claudin18.2-expressing cells. Additionally, the company has two preclinical antibody programs, FL-302 and FL-501, aimed at developing transformative cancer treatments. Operating as a single segment, the company's sole focus is on developing innovative drugs to address unmet needs in cancer therapy. .
About IVA Inventiva S.A. American Depository Shares
Inventiva SA is a France-based biopharmaceutical company specialized in developing drugs that impact on nuclear receptors, transcription factors and epigenetic modulation. The company is focused on developing its product candidate, lanifibranor, for the treatment of patients with non-alcoholic steatohepatitis, or NASH, a disease for which there are currently no approved therapies. The company is also involved in developing a portfolio of pre-clinical therapy programs. It operates in the segment of Service delivery and clinical stage research, notably into therapies in the areas of oncology, fibrosis, and rare diseases. All the company's operations are in France. Majority of the group's revenue is derived from its research partnerships with AbbVie and BI.